152 related articles for article (PubMed ID: 21673355)
21. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for cervical abnormalities among Hong Kong Chinese women: a large-scale community-based cervical screening program.
Wong HY; Loke AY; Chan NH
J Womens Health (Larchmt); 2011 Jan; 20(1):53-9. PubMed ID: 21091197
[TBL] [Abstract][Full Text] [Related]
23. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
24. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
25. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.
Lin CT; Tseng CJ; Lai CH; Hsueh S; Huang HJ; Law KS
J Reprod Med; 2000 Apr; 45(4):345-50. PubMed ID: 10804494
[TBL] [Abstract][Full Text] [Related]
26. HPV testing alone is not as safe as cytology and selective HPV testing: FOR: The sensitivity of HPV testing is not high enough.
Dudding N
BJOG; 2016 Jan; 123(1):68. PubMed ID: 26527310
[No Abstract] [Full Text] [Related]
27. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
28. A new generation of studies of human papillomavirus DNA testing in cervical cancer screening.
Franco EL
J Natl Cancer Inst; 2009 Dec; 101(23):1600-1. PubMed ID: 19903806
[No Abstract] [Full Text] [Related]
29. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
[TBL] [Abstract][Full Text] [Related]
30. Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions.
Levi AW; Harigopal M; Hui P; Schofield K; Chhieng DC
Cancer Cytopathol; 2011 Aug; 119(4):228-34. PubMed ID: 21732551
[TBL] [Abstract][Full Text] [Related]
31. Is it time to introduce HPV self-sampling for primary cervical cancer screening?
Petignat P; Vassilakos P
J Natl Cancer Inst; 2012 Feb; 104(3):166-7. PubMed ID: 22271766
[No Abstract] [Full Text] [Related]
32. Cost-effectiveness analysis of cervical cancer screening strategies based on the Papanicolaou smear test in Korea.
Ko MJ; Kim J; Kim Y; Lee YJ; Hong SR; Lee JK
Asian Pac J Cancer Prev; 2015; 16(6):2317-22. PubMed ID: 25824757
[TBL] [Abstract][Full Text] [Related]
33. Screening and prevention methods for cervical cancer.
Schiffman M; Solomon D
JAMA; 2009 Oct; 302(16):1809-10. PubMed ID: 19861676
[No Abstract] [Full Text] [Related]
34. [High-risk HPV genotyping PCR testing as a means of cervical cancer and precancerous lesions early screening].
Ma L; Cong X; Bian M; Shi M; Wang X; Liu J; Liu H
Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):246-52. PubMed ID: 26080934
[TBL] [Abstract][Full Text] [Related]
35. HPV testing in cervical screening.
Cuzick J
Pharmacoepidemiol Drug Saf; 2001; 10(1):33-6. PubMed ID: 11417064
[No Abstract] [Full Text] [Related]
36. Global strategies for cervical cancer prevention.
Pimple S; Mishra G; Shastri S
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):4-10. PubMed ID: 26642063
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study).
Orlando G; Tanzi E; Chatenoud L; Gramegna M; Rizzardini G;
BMC Cancer; 2012 May; 12():204. PubMed ID: 22646512
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
39. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
[TBL] [Abstract][Full Text] [Related]
40. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
